Biogen stocks plummet after failed Alzheimer ’s trials

After losing more than $18 billion of its value last week after ending two late-stage trials of their experimental Alzheimer ’s disease treatment, Biogen said it would buy back shares worth $5 billion.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news